{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:54:54Z","timestamp":1784098494313,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T00:00:00Z","timestamp":1590883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T00:00:00Z","timestamp":1590883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Shengjing Hospital of China Medical University, Shenyang","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11095-020-02838-4","type":"journal-article","created":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T15:02:17Z","timestamp":1590937337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle"],"prefix":"10.1007","volume":"37","author":[{"given":"Chenyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,31]]},"reference":[{"key":"2838_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1939-1676.2003.tb02513.x","volume":"17","author":"SS Sulaimon","year":"2003","unstructured":"Sulaimon SS, Kitchell BE. The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Int Med. 2003;17:760\u201372.","journal-title":"J Vet Int Med"},{"key":"2838_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/bjc.1994.363","volume":"70","author":"LW Seymour","year":"1994","unstructured":"Seymour LW, Ulbrich K, Steyger PS, Brereton M, Subr V, Strohalm J, et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer. 1994;70:636\u201341.","journal-title":"Br J Cancer"},{"key":"2838_CR3","first-page":"949","volume":"20","author":"T Murata","year":"1990","unstructured":"Murata T, Hibasami H, Maekawa S, Tagawa T, Nakashima K. Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int. 1990;20:949\u201355.","journal-title":"Biochem Int"},{"key":"2838_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093960","volume":"9","author":"N Yin","year":"2014","unstructured":"Yin N, Ma W, Pei J, Ouyang Q, Tang C, Lai L. Synergistic and antagonistic drug combinations depend on network topology. PLoS One. 2014;9:e93960.","journal-title":"PLoS One"},{"key":"2838_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2838_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman AI. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"2838_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nri3790","volume":"15","author":"LT Nguyen","year":"2015","unstructured":"Nguyen LT, Ohashi PS. Clinical blockade of PD1 and Lag3- potential mechanisms of action. Nat Rev Immunol. 2015;15:45\u201356.","journal-title":"Nat Rev Immunol"},{"key":"2838_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ctrv.2013.07.005","volume":"40","author":"JY Blay","year":"2014","unstructured":"Blay JY, Rutkowski P. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev. 2014;40:242\u20137.","journal-title":"Cancer Treat Rev"},{"key":"2838_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.apjtb.2015.10.006","volume":"6","author":"SAS Shandiz","year":"2016","unstructured":"Shandiz SAS, Khosravani M, Mohammadi S, Noorbazargan H, Mirzaie A, Inanlou DN, et al. Evaluation of imatinib mesylate (Gleevec) on KAI1\/CD82 gene expression in breast cancer MCF-7 cells using quantitative realtime PCR. Asian Pac J Trop Biomed. 2016;6:159\u201363.","journal-title":"Asian Pac J Trop Biomed"},{"key":"2838_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3892\/mmr.2015.4672","volume":"13","author":"SM Woo","year":"2015","unstructured":"Woo SM, Choi YK, Kim AJ, Cho SG, Ko SG. P53 causes butein-mediated apoptosis of chronic myeloid leukemia cells. Mol Med Rep. 2015;13:1091\u20136.","journal-title":"Mol Med Rep"},{"key":"2838_CR11","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76:6964\u201374.","journal-title":"Cancer Res"},{"key":"2838_CR12","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242\u201356.","journal-title":"Cell"},{"key":"2838_CR13","doi-asserted-by":"publisher","first-page":"10135","DOI":"10.1021\/acsnano.7b04717","volume":"11","author":"G Kwak","year":"2017","unstructured":"Kwak G, Kim D, Nam G, Wang SY, Kim I, Kim SH, et al. Programmed cell death protein Ligand-1 silencing with Polyethylenimine\u2013Dermatan sulfate complex for dual inhibition of melanoma growth. ACS Nano. 2017;11:10135\u201346.","journal-title":"ACS Nano"},{"key":"2838_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with Lambrolizumab (anti\u2212PD-1) in melanoma. N Engl J Med. 2013;369:134\u201344.","journal-title":"N Engl J Med"},{"key":"2838_CR15","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti\u2212PD-L1 antibody in patients with advanced Cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"2838_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab Plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2013;369:122\u201333.","journal-title":"N Engl J Med"},{"key":"2838_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","volume":"3","author":"L Khoja","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer. 2015;3:36.","journal-title":"J Immunother Cancer"},{"key":"2838_CR18","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1016\/j.biomaterials.2011.04.047","volume":"332","author":"Y Sakurai","year":"2011","unstructured":"Sakurai Y, Hatakeyama H, Sato Y, Akita H, Takayama K, Kobayashi S, et al. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the Fusogenic peptide Shgala. Biomaterials. 2011;332:5733\u201342.","journal-title":"Biomaterials"},{"key":"2838_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1248\/bpb.35.445","volume":"35","author":"K Kusumoto","year":"2012","unstructured":"Kusumoto K, Akita H, El-Sayed A, Harashima H. Effect of the anchor in polyethylene glycol-lipids on the transfection activity of PEGylated cationic liposomes encapsulating DNA. Biol Pharm Bull. 2012;35:445\u20138.","journal-title":"Biol Pharm Bull"},{"key":"2838_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.colsurfb.2017.06.022","volume":"158","author":"SR Pinnapireddy","year":"2017","unstructured":"Pinnapireddy SR, Duse L, Strehlow B, Sch\u00e4fer J, Bakowsky U. Composite liposome-PEI\/nucleic acid lipopolyplexes for safe and efficient gene delivery and gene knockdown. Colloids Surf B Biointerfaces. 2017;158:93\u2013101.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2838_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jconrel.2020.01.024","volume":"320","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wu Q, Wang J, Li L, Sun X, Zhang Z, et al. Co-delivery of p38\u03b1 MAPK and p65 siRNA by novel liposomal glomerulus-targeting nano carriers for effective immunoglobulin a nephropathy treatment. J Control Release. 2020;320:457\u201368.","journal-title":"J Control Release"},{"key":"2838_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen- specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537\u201344.","journal-title":"Blood"},{"key":"2838_CR23","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"2838_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor Pten function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84\u20138.","journal-title":"Nat Med"},{"key":"2838_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.imbio.2011.10.016","volume":"217","author":"J Chen","year":"2012","unstructured":"Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, et al. Interferon-\u03b3-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology. 2012;217:385\u201393.","journal-title":"Immunobiology."},{"key":"2838_CR26","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.4049\/jimmunol.0904114","volume":"184","author":"S Pilon-Thomas","year":"2010","unstructured":"Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol. 2010;184:3442\u20139.","journal-title":"J Immunol"},{"key":"2838_CR27","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1021\/acsami.6b09163","volume":"11","author":"B Gupta","year":"2017","unstructured":"Gupta B, Ramasamy T, Poudel BK, et al. Development of bioactive PEGylated nanostructured platforms for sequential delivery of doxorubicin and Imatinib to overcome drug resistance in metastatic tumors. ACS Appl Mater Interfaces. 2017;11:9280\u201390.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2838_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jconrel.2017.04.043","volume":"258","author":"T Ramasamy","year":"2017","unstructured":"Ramasamy T, Ruttala HB, Gupta B, Poudel BK, Choi HG, Yong CS, et al. Smart chemistry-based nanosized drug delivery systems for systemic applications: a comprehensive review. J Control Release. 2017;258:226\u201353.","journal-title":"J Control Release"},{"key":"2838_CR29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/mt.2012.79","volume":"20","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther. 2012;20:1298\u2013304.","journal-title":"Mol Ther"},{"key":"2838_CR30","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1021\/acsbiomaterials.9b00982","volume":"10","author":"T Ramasamy","year":"2019","unstructured":"Ramasamy T, Ruttala HB, Kaliraj K, et al. Polypeptide derivative of metformin with the combined advantage of a gene carrier and anticancer activity. ACS Biomater Sci Eng. 2019;10:5159\u201368.","journal-title":"ACS Biomater Sci Eng"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-020-02838-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02838-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T23:25:47Z","timestamp":1622417147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-020-02838-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,31]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2838"],"URL":"https:\/\/doi.org\/10.1007\/s11095-020-02838-4","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,31]]},"assertion":[{"value":"26 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"109"}}